estim
million
case
malaria
global
infecti
diseas
respons
death
arsen
antimalari
drug
limit
current
effect
treatment
pathogen
agent
plasmodium
falciparum
includ
artemisinin
combin
therapi
act
although
resist
artemisinin
report
four
countri
southeast
asia
region
cambodia
myanmar
thailand
vietnam
need
new
antimalari
therapi
stimul
research
search
synthet
molecul
effect
acquir
resist
artemisinin
deriv
would
result
promis
antimalari
activ
context
chalcon
bioprecursor
flavonoid
use
scaffold
medicin
chemist
mani
year
chalcon
analog
associ
broad
rang
biolog
activ
includ
antimalari
activ
antimalari
activ
chalcon
associ
inhibit
either
plasmodi
aspart
proteas
cystein
proteas
plasmodi
aspart
cystein
proteas
attract
target
antimalari
therapi
due
role
degrad
hemoglobin
erythrocyt
parasit
develop
addit
sulfonamid
group
deriv
alreadi
shown
antimalari
activ
recent
strategi
adopt
search
new
antimalari
drug
design
hybrid
one
main
challeng
develop
new
antimalari
drug
achiev
viabl
lead
candid
good
pharmacokinet
properti
absorpt
distribut
metabol
excret
toxic
admet
well
known
artemisinin
deriv
act
short
time
requir
frequent
dose
maintain
efficaci
therefor
search
artemisinin
deriv
well
new
synthet
compound
enhanc
pharmaceut
properti
receiv
consider
attent
herein
report
antimalari
activ
deriv
figur
molecular
dock
studi
initi
analys
admet
properti
studi
led
select
lead
candid
optim
oral
absorpt
properti
half
maxim
inhibitori
concentr
lethal
drug
concentr
valu
determin
nine
deriv
given
tabl
compound
show
potenc
p
falciparum
chloroquineresist
clone
valu
rang
parallel
test
toxic
compound
hela
cell
line
valu
higher
valu
compound
best
select
index
advanc
detail
physicochem
analysi
recent
antimalari
screen
synthes
chalcon
show
major
compound
activ
vitro
p
falciparum
low
cytotox
howev
lack
oral
bioavail
due
poor
admet
properti
compound
becom
market
oral
drug
physicochem
characterist
favor
drug
absorpt
permeabl
find
prompt
us
evalu
physicochem
properti
chalcon
deriv
tabl
identifi
compound
optim
oral
absorpt
properti
guid
futur
structur
modif
order
improv
admet
properti
gener
consensu
molecular
properti
drug
candid
molecular
weight
lipophil
import
admet
properti
properti
solubl
clearanc
volum
distribut
also
import
consid
profil
drug
candid
addit
use
comput
tool
contribut
improv
drug
design
order
attain
efficaci
antimalari
activ
ration
drug
discoverydevelop
process
guid
optim
lead
compound
success
drug
candid
rule
predict
duglik
physiochem
properti
introduc
lipinski
rule
five
well
paramet
like
lipophil
effici
lipe
shown
use
tool
aid
choos
oral
drug
candid
sulfonamid
deriv
synthes
clogp
valu
mean
valu
molecular
weight
mw
mean
valu
gleeson
et
al
suggest
compound
clogp
mw
da
favor
admet
profil
figur
show
distribut
clogp
versu
mw
nine
synthes
compound
among
five
compound
clogp
addit
rang
lipophil
mw
also
desir
drug
candid
high
vitro
potenc
high
potenc
compound
reduc
chanc
drug
lack
specif
target
allow
administr
smaller
dose
thu
reduc
risk
advers
effect
although
vitro
potenc
lipophil
compound
import
paramet
evalu
concept
lipophil
effici
lipe
aid
establish
balanc
relationship
potenc
observ
vitro
lipophil
properti
evalu
chemic
compound
ryckman
et
al
report
high
qualiti
lead
compound
possess
higher
lipe
valu
plot
clogp
figur
nine
sulfonamid
deriv
show
distribut
along
line
ident
lipe
valu
compound
low
lipe
valu
higher
clogp
valu
interest
observ
substitut
pyrrolidin
group
morpholin
group
similar
potenc
clogp
valu
compound
reduc
compound
recent
anim
safeti
studi
demonstr
risk
side
effectstox
reduc
compound
clogp
addit
find
suggest
presenc
polar
group
oxygen
atom
morpholin
ring
may
import
bind
site
interact
compound
inde
compound
highest
lipe
valu
data
set
deem
optim
compound
dock
result
also
show
addit
bind
interact
compound
plasmepsin
due
presenc
morpholin
ring
addit
bind
interact
compound
shown
figur
addit
dock
result
suggest
michael
reaction
mechan
ligand
proteas
figur
highlight
short
distanc
carbonyl
moieti
michael
acceptor
carboxyl
anion
michael
donor
suitabl
nucleophil
attack
result
alkyl
process
chalcon
report
inhibit
plasmodi
aspart
proteas
cystein
proteas
therefor
perform
dock
studi
determin
bind
orient
activ
site
amino
acid
residu
enzym
bind
free
energi
dock
compound
given
tabl
bind
free
energi
compound
determin
optim
chalcon
deriv
kcalmol
kcalmol
kcalmol
show
better
interact
aspart
proteas
figur
although
compound
exhibit
best
physic
chemistri
paramet
oral
administr
tabl
compound
store
mgml
stock
solut
dimethylsulfoxid
dmso
sigma
st
loui
mo
usa
compound
dilut
dmso
use
final
concentr
vv
human
red
blood
cell
infect
p
falciparum
clone
chloroquineresist
maintain
continu
cultur
previous
describ
human
red
blood
cell
plasma
cede
synchron
parasit
achiev
sorbitol
treatment
parasitaemia
determin
microscop
giemsastain
smear
antimalari
effect
synthet
sulfonamid
deriv
control
compound
chloroquin
measur
use
tradit
method
minor
modif
briefli
ringstag
parasit
sorbitolsynchron
blood
cultur
ad
cultur
plate
parasitaemia
haematocrit
incub
test
compound
compound
dilut
complet
media
mgml
stock
solut
dmso
variou
concentr
h
incub
giemsastain
blood
smear
taken
microscop
evalu
parasitaemia
experi
perform
triplic
result
express
mean
lethal
drug
concentr
reduc
parasit
viabil
cytotox
compound
assess
hela
human
cell
line
cervix
adenocarcinoma
atcc
use
mtt
bromid
sigma
st
loui
mo
usa
colorimetr
method
briefli
cell
plate
plate
cellswel
incub
h
humidifi
atmospher
h
well
wash
cultur
medium
rpmi
inactiv
fetal
calf
serum
mm
lglutamin
incub
compound
variou
concentr
h
incub
plate
treat
mtt
colorimetr
read
perform
micropl
reader
spectramax
molecular
devic
sunnyval
ca
usa
nm
cytotox
score
percentag
reduct
absorb
versu
untreat
control
cultur
experi
perform
triplic
result
express
mean
lethal
drug
concentr
reduc
cell
viabil
valu
calcul
use
originlab
corpor
northampton
usa
softwar
select
index
si
correspond
ratio
cytotox
antiparasit
activ
compound
calcul
follow
si
plasmodium
falciparum
comput
flexibl
dock
redock
execut
autodock
vina
softwar
dock
procedur
involv
prepar
ligand
macromolecul
use
simul
box
suffici
larg
involv
entir
region
interact
ligand
receptor
compound
dock
catalyt
bind
site
pdb
pdb
pdb
predict
bind
mode
approxim
bind
free
energi
structur
ligand
minim
use
softwar
method
lowest
energi
conform
identifi
bind
energi
evalu
clogp
valu
compound
estim
use
chembiodraw
ultra
softwar
version
averag
compar
use
anova
differ
valu
evalu
use
graphpad
prism
demo
statist
signific
defin
level
p
assay
compound
show
antimalari
activ
among
nine
compound
assay
four
potenc
rang
physicochem
lipe
analysi
dataset
allow
us
establish
compound
highest
qualiti
compound
seri
molecular
dock
provid
insight
bind
mode
compound
bind
site
data
indic
presenc
morpholin
ring
substitu
requir
optim
bind
site
interact
optim
lead
compound
may
provid
potent
select
plasmepsin
inhibitor
potenti
better
druggabilti
